| |
Adobe Reader 6.0 or higher is required to view our PDF documents.
|
| |
July 8, 2003 - Target Discovery, Inc. Appoints Juan Santiago, Ph.D, And Evan Williams, Ph.D., to Scientific Advisory Board
Target Discovery, Inc., a discovery biology company, today announced that Juan G. Santiago, Ph.D., and Evan R. Williams, Ph.D., have joined its scientific advisory board. The new SAB members are advising the company on its broad range of new enabling technologies for the discovery and optimization of targets, lead candidates and clinical sub-typing used in drug development, and on specific products being prepared for market introduction.
"Drs. Santiago and Williams are highly respected scientists and leading thinkers in areas that are of significant interest to our company: electrophoresis and mass spectrometry. The process of drug discovery and development today is severely hampered by the current technical limitations of these widely used underlying platform technologies," said Jeffrey N. Peterson, CEO of Target Discovery. "As we continue to overcome barriers to the quality, speed and cost of experimental results from mass spec and capillary electrophoresis platforms, while opening up the breadth of the proteome that can be addressed, the guidance of these two outstanding researchers will be a tremendous asset."
Dr. Williams holds faculty appointments at the University of California at Berkeley in chemistry and biophysics, as well as a faculty position in chemistry at Lawrence Berkeley National Laboratory. His research interests span the development and uses of novel mass spectrometry instrumentation, including methods of protein identification, and have been the basis of more than 75 scientific publications. He has received numerous awards throughout his scientific career and currently serves on the editorial boards of several influential journals, including the International Journal of Mass Spectrometry. Dr. Williams completed his postdoctoral training at Stanford, his M.S. and Ph.D. in chemistry at Cornell, and his bachelor's degree in chemistry at the University of Virginia.
Dr. Santiago holds a faculty position at Stanford University in the mechanical engineering department, and also serves as the director of Stanford's Microfluidics Laboratory. His research interests lie in the fluid dynamics of micro-scale systems and the design and manufacture of such systems. In his academic career, Dr. Santiago received awards from the National Science Foundation and the University of Illinois at Urbana-Champaign. Dr. Santiago received his master's degree and Ph.D. in mechanical engineering from the University of Illinois and his bachelor's degree in mechanical engineering from the University of Florida.
"I am very impressed with Target Discovery's progress towards making capillary electrophoresis a protein separation and quantitation workhorse that can illuminate the full range of prospective therapeutic targets for drug discovery companies. In the first of several upcoming product offerings, the company has taken on one of the most significant experimental limitations of capillary electrophoresis. Their new technology should enable researchers to query a subset of proteins and other analytes that were previously inaccessible through current methods, leading to enhanced target identification," said Dr. Santiago. "I'm excited to have the chance to add my input to this company as they tackle biological problems from an engineering perspective."
"Through my years in the field, I have seen the capabilities and applications of mass spectrometry evolve significantly, but I was impressed with Target Discovery's innovative use of a subtlety from sub-nuclear physics to open up an exciting new range of mass spec applications. In addition, sensitivity limitations have remained a critical constraint in mass spectrometry, and Target Discovery's novel analysis of this important problem has resulted in promising new technologies to increase experimental sensitivity," said Dr. Williams. "Importantly, they are turning these approaches into a practical business plan, and I'm looking forward to contributing my expertise as they move forward."
About Target Discovery, Inc.
Target Discovery is a discovery biology company that seeks to alleviate critical bottlenecks imposed by current technologies upon drug development and life science research. The company is developing new platform technologies for the elucidation of high quality biological data and for the conversion of that information into a confirmed understanding of biological pathways. Pathway understanding enables new efficiencies in the identification, selection and development of optimal disease targets, biomarkers and drug candidates. Target Discovery is introducing selected technology platforms in reagent and software product formats, starting in 2003, and will initiate discovery collaborations with interested partners. The company is based in Palo Alto, California. More information is available at http://www.targetdiscovery.com
For further information, please contact Jeffrey N. Peterson, Chief Executive Officer of Target Discovery, +1-650-812-8121; or Liz H. Z. Thompson, Ph.D., Media & Investor Relations of Atkins + Associates, +1-858-527-3492, for Target Discovery.
|
|
|
|
|
